Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
grade B 8.29 4.15% 0.33
ARDX closed up 4.15 percent on Wednesday, February 19, 2020, on 1.3 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical ARDX trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish 4.15%
Crossed Above 50 DMA Bullish 4.15%
180 Bullish Setup Bullish Swing Setup 4.15%
Expansion Pivot Buy Setup Bullish Swing Setup 4.15%
Pocket Pivot Bullish Swing Setup 4.15%
Upper Bollinger Band Walk Strength 4.15%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Biotechnology Biopharmaceutical Chronic Kidney Disease Astrazeneca End Stage Renal Disease Metabolic Diseases Rockwell Medical Södertälje Municipality Hyperphosphatemia

Is ARDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 8.48
52 Week Low 2.1
Average Volume 836,100
200-Day Moving Average 4.81
50-Day Moving Average 7.40
20-Day Moving Average 7.37
10-Day Moving Average 7.55
Average True Range 0.45
ADX 14.47
+DI 25.63
-DI 15.49
Chandelier Exit (Long, 3 ATRs ) 6.96
Chandelier Exit (Short, 3 ATRs ) 8.00
Upper Bollinger Band 8.01
Lower Bollinger Band 6.73
Percent B (%b) 1.22
BandWidth 17.37
MACD Line 0.16
MACD Signal Line 0.07
MACD Histogram 0.0907
Fundamentals Value
Market Cap 393.32 Million
Num Shares 47.4 Million
EPS -2.44
Price-to-Earnings (P/E) Ratio -3.40
Price-to-Sales 0.00
Price-to-Book 1.59
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.94
Resistance 3 (R3) 8.87 8.58 8.83
Resistance 2 (R2) 8.58 8.42 8.62 8.79
Resistance 1 (R1) 8.44 8.32 8.51 8.51 8.76
Pivot Point 8.15 8.15 8.19 8.19 8.15
Support 1 (S1) 8.01 7.99 8.08 8.08 7.82
Support 2 (S2) 7.72 7.89 7.76 7.79
Support 3 (S3) 7.58 7.72 7.75
Support 4 (S4) 7.65